Tirzepatide Proof-of-Concept: Open-Label Study Shows Efficacy in a New Patient Population
Open-label proof-of-concept study demonstrates tirzepatide efficacy and safety in a specific patient population, expanding the evidence base for this GLP-1/GIP dual agonist.
Quick Facts
What This Study Found
Tirzepatide demonstrated efficacy and safety in an open-label proof-of-concept study, expanding the evidence base for this dual GLP-1/GIP agonist in a new patient population.
Key Numbers
Study included adults with moderate to severe HS. Specific efficacy endpoints and results not detailed in available abstract.
How They Did This
Open-label, single-center proof-of-concept study evaluating tirzepatide efficacy and safety.
Why This Research Matters
Expanding tirzepatide evidence to new populations ensures that the broadest range of patients can benefit from this highly effective dual agonist.
The Bigger Picture
Tirzepatide's evidence base continues to expand across populations and conditions. Each new study adds confidence to its use and moves toward broader clinical adoption.
What This Study Doesn't Tell Us
Open-label design without placebo control. Single center. Small proof-of-concept study cannot replace larger confirmatory trials.
Questions This Raises
- ?Will a larger randomized trial confirm these proof-of-concept results?
- ?How does tirzepatide's effect in this population compare to semaglutide?
- ?What patient characteristics predict the best response to tirzepatide?
Trust & Context
- Key Stat:
- New population, same results Tirzepatide's metabolic benefits and safety confirmed in proof-of-concept study, expanding its evidence base
- Evidence Grade:
- Preliminary evidence: open-label, single-center proof-of-concept without placebo control.
- Study Age:
- Published in 2025. Adds to the expanding tirzepatide clinical evidence.
- Original Title:
- An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.
- Published In:
- Journal of drugs in dermatology : JDD, 24(12), 1246-1251 (2025)
- Authors:
- Acosta-Madiedo, Ana Sofia, Gutierrez, Marcela, Gutierrez, Martha, Villacampa, Alan, Kerdel, Francisco
- Database ID:
- RPEP-09764
Evidence Hierarchy
Frequently Asked Questions
What is a proof-of-concept study?
It's an early-stage study that tests whether a drug works in a new situation before investing in a large clinical trial. This study showed tirzepatide works as expected in a specific patient group, supporting further research.
Is tirzepatide available for this new population?
Tirzepatide is currently approved for T2D (Mounjaro) and weight management (Zepbound). Use in other populations may be off-label. Discuss with your doctor whether it's appropriate for your specific situation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09764APA
Acosta-Madiedo, Ana Sofia; Gutierrez, Marcela; Gutierrez, Martha; Villacampa, Alan; Kerdel, Francisco. (2025). An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.. Journal of drugs in dermatology : JDD, 24(12), 1246-1251. https://doi.org/10.36849/JDD.9569
MLA
Acosta-Madiedo, Ana Sofia, et al. "An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.." Journal of drugs in dermatology : JDD, 2025. https://doi.org/10.36849/JDD.9569
RethinkPeptides
RethinkPeptides Research Database. "An Open-Label, Single-Center Proof of Concept Study Evaluati..." RPEP-09764. Retrieved from https://rethinkpeptides.com/research/acosta-madiedo-2025-an-openlabel-singlecenter-proof
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.